tezampanel

structure given in first source; an AMPA receptor antagonist

Also Known As:

(3S,4aR,6R,8aR)-6-(2-(1(2)H-tetrazole-5yl)ethyl)decahydroisoquinoline-3carboxylic acid; 6-(2-(1H-tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; LY 215490; LY 293558; LY 326325; LY-215490; LY-293558; LY-326325; LY293558; NGX424

Networked: 32 relevant articles (10 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - tezampanel: 32
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - tezampanel: 32

Experts

1.	Apland, James P: 8 articles (11/2020 - 02/2011)
2.	Aroniadou-Anderjaska, Vassiliki: 8 articles (11/2020 - 02/2011)
3.	Figueiredo, Taiza H: 8 articles (11/2020 - 02/2011)
4.	Braga, Maria F M: 7 articles (11/2020 - 02/2011)
5.	De Araujo Furtado, Marcio: 2 articles (11/2020 - 10/2018)
6.	Prager, Eric M: 2 articles (11/2017 - 02/2015)
7.	Corleto, Jose A: 2 articles (01/2015 - 09/2012)
8.	Kakinohana, Osamu: 2 articles (01/2015 - 09/2012)
9.	Lukacova, Nadezda: 2 articles (01/2015 - 09/2012)
10.	Marsala, Martin: 2 articles (01/2015 - 09/2012)

Related Diseases

1.	Seizures (Absence Seizure) 02/01/2015 - "In the present study, we examined whether the protection against nerve agent-induced seizures and neuropathology conferred by LY293558 translates into protection against pathophysiological alterations in the basolateral amygdala (BLA) and the development of anxiety, which is the most prevalent behavioral deficit resulting from exposure. " 02/01/2015 - "Along with our previous findings, the present data demonstrate the remarkable efficacy of LY293558 in counteracting nerve agent-induced seizures, neuropathology, pathophysiological alterations in the BLA, and anxiety-related behavioral deficits." 02/01/2011 - "Therefore, we tested whether LY293558 is effective against soman-induced seizures and neuropathology, when administered 1 h after soman exposure, in rats. " 11/01/2017 - "Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats." 01/01/2020 - "Treatment of soman-exposed immature, young-adult, and aged rats with LY293558, terminates SE with limited recurrence of seizures, significantly protects from brain damage, and prevents long-term behavioral deficits, even when LY293558 is administered 1 h post-exposure. "
2.	Pain (Aches) 10/01/2006 - "LY293558 was most effective for evoked pain when administered intrathecally. " 09/01/2001 - "By January 2000, LY-293558 was undergoing phase II trials for pain [414000]." 10/01/2007 - "The effects of epidural tezampanel on the cumulative pain scoring, based on guarding, the withdrawal threshold to von Frey filament application, and the withdrawal latency to heat, were measured. " 10/01/2007 - "The effects of epidural tezampanel on pain-related behaviors in rats that underwent plantar incision were also studied. " 09/01/2000 - "High-dose LY293558 was superior to placebo at individual time points (45 to 240 minutes) for pain evoked by mouth opening but not for spontaneous pain. "
3.	Hyperalgesia 10/01/2006 - "Parenteral, intrathecal, or intraplantar administration of LY293558 was tested against the mechanical hyperalgesia that characterizes the model. " 10/01/2006 - "The purpose of this study was to assess the efficacy of a non-NMDA receptor antagonist LY293558 on mechanical hyperalgesia after plantar incision in the rat. " 11/01/1998 - "The effects of the competitive AMPA-KA antagonist LY293558 in two types of experimental pain in human volunteers, brief pain sensations in normal skin, and mechanical allodynia-pinprick hyperalgesia were studied after the injection of intradermal capsaicin. " 11/01/1998 - "AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans." 12/01/2012 - "This study evaluated the effects of an oral prodrug to tezampanel, a selective α-amino-3-hydroxy-5-methly-4-isoxazole-proprionic acid/kainate receptor antagonist, on intradermal capsaicin-induced pain and hyperalgesia. "
4.	Migraine Disorders (Migraine) 07/01/2004 - "We therefore tested LY293558 in acute migraine. " 07/01/2004 - "The efficacy and safety results of LY293558 in this small migraine proof of concept trial, together with supportive preclinical data, provide evidence for a potential role of nonvasoactive AMPA/KA antagonists in treating migraine. " 07/01/2004 - "We conducted a randomized, triple-blind, parallel-group, double-dummy, multicentre trial of 1.2 mg/kg intravenous (IV) LY293558, 6 mg subcutaneous (SC) sumatriptan, or placebo in the treatment of acute migraine. " 07/01/2004 - "LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine." 07/01/2004 - "LY293558 and sumatriptan were superior to placebo (P < 0.01 for all comparisons) on all other measures of improvement in pain and migraine associated symptoms. "
5.	Anxiety Disorders (Anxiety Disorder) 04/01/2006 - "In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders."

Related Drugs and Biologics

1.	Soman
2.	Nerve Agents
3.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
4.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
5.	Midazolam (Versed)
6.	caramiphen
7.	tezampanel
8.	Kainic Acid Receptors (Kainate Receptor)
9.	Acids
10.	Diazepam (Valium)

Related Therapies and Procedures

1.	Emergency Treatment
2.	Therapeutics
3.	Hemoperfusion
4.	Analgesia